Pharmaceutical Company Running Phase 2 Study for Critically Ill COVID-19 Subjects Gets Unified Decentralized Platform

At the start of the COVID-19 pandemic, a global eClinical provider was approached by a pharmaceutical sponsor with the request to provide a decentralized platform including eSource/ePRO for direct-data-entry, randomization, eConsent, telehealth, remote monitoring, and data management for a multisite trial for patients with SARS-CoV-2 in the hospital.

While the sponsor was looking for a team with decentralized clinical trial experience, they specifically needed a unified platform that could operate through one central login for all solutions. In addition to software solutions, they also needed a partner with data management capabilities.

Learn how this provider was able to deliver an experienced team, all working together to ensure rapid implementation and effective conduct services.